This form triggers the Keap1/Nrf2 transcriptional pathway to create phase 2 antioxidant enzymes [103] found that histologically, CA increased dendritic and synaptic markers, and decreased astrogliosis, Aβ plaque number, and phospho-tau staining in the hippocampus, thus explaining CA therapeutic benefits in rodent AD models. The gene discussed is MAPT; the disease is Alzheimer disease.